# US 2026/0083708 A1 · Il-17 modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083708 A1
- Document ID: US20260083708A1
- Status: Published application
- Kind: A1
- Application number: 19/405,049
- Filed: 2025-12-01
- Published: 2026-03-26
- Earliest claimed: 2024-04-03
- Applicants: Nnocare Pharma Inc.
- Inventors: Yucheng PANG; Feiyang XU; Xiangyang CHEN
- Web page: https://patentgrep.com/patent/US20260083708A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds suitable for inhibiting or regulating the activity of IL-17. The present invention is directed to compounds shown in Formula (I) and their pharmaceutically acceptable salts thereof. The present invention further relates to methods for treating and/or preventing various human diseases, including inflammatory and autoimmune disorders. The present invention also provides methods for preparing the compounds of the present invention.

## Claims

### Claim 1

A compound according to Formula (IIb),
or a pharmaceutically acceptable salt thereof,
wherein:
B is C1-6 alkyl or C3-10 cycloalkyl, where one or more hydrogens of the alkyl and cycloalkyl are optionally substituted by C3-10 cycloalkyl, C1-6 alkyl, C1-2 alkenyl or halogen, where one or more hydrogens of the alkyl, cycloalkyl and alkenyl are further optionally substituted by halogen or C1-6 alkyl;
X is CH or N;
Y1 is N or CR31;
Y2 is N, NR32 or CR31;
Y3 is N, NR32, O or S;
R31 is H, halogen or C1-6 alkyl;
R32 is C1-6 alkyl, C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, where one or more hydrogens of the alkyl, cycloalkyl and heterocyclyl are optionally substituted by C3-6 cycloalkyl, halogen, C1-6 alkyl, 4- to 6-membered heterocyclyl, —ORb or —NR13R14, where one or more hydrogens of cycloalkyl and heterocyclyl are further optionally substituted by halogen or C1-6 alkyl;
R1 is C1-6 alkyl, where one or more hydrogens of the alkyl are optionally substituted by halogen, D, CN, 4- to 6-membered heterocyclyl, —ORd or —NR15R16.
R2 is methyl or cyclopropyl;
R3 is H, F or —OCH3;
R6 is 5-membered heteroaryl containing one to three heteroatoms selected from N, O and S, where one or more hydrogens of the heteroaryl are optionally substituted by C1-6 alkyl, fluorinated C1-6 alkyl, deuterated C1-6 alkyl or C3-6 cycloalkyl;
Rd is H, C1-6 alkyl, C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, where one or more hydrogens of the alkyl, cycloalkyl and heterocyclyl are optionally substituted by F, D, C1-6 alkyl or C3-6 cycloalkyl; and
Rb, R13, R14, R15 and R16 are independently selected from H, C1-6 alkyl and C3-6 cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1 selected from a group consisting of:
or a pharmaceutically acceptable salt, or a stable isotope derivative thereof, or a stereoisomer thereof.

### Claim 3

A compound having the following structure:
or a pharmaceutically acceptable salt, or a stable isotope derivative thereof, or a stereoisomer thereof.

### Claim 4

A compound having the following structure:
or a pharmaceutically acceptable salt, or a stable isotope derivative thereof, or a stereoisomer thereof.

### Claim 5

A compound having the following structure:
or a pharmaceutically acceptable salt, or a stable isotope derivative thereof, or a stereoisomer thereof.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or pharmaceutically acceptable salts, or stable isotope derivatives, or stereoisomers thereof, and a pharmaceutically acceptable carrier or excipient thereof.

### Claim 7 (depends on 1)

A method for treating a disease mediated by IL-17, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1, or pharmaceutically acceptable salts, or stable isotope derivatives, or stereoisomers thereof.
